http://www.lsis.com/goto/r117/rss 2010-06-23T11:11:14+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97f%FB%11zys UNION-TRIBUNE - San Diego drugmaker Amylin Pharmaceuticals has laid off about 60 employees, or 4 percent of its workforce, in recent weeks as part of an effort to make the company more efficient, a spokeswoman said Friday. The cuts occurred in a variety of departments, including research, said Alice Izzo, vice president of corporate affairs. As a result, Amylin now will rely more heavily on outside sources for new pharmaceutical discoveries, she said. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97f%FB%11zzx Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's (ADA's) 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29. The Company will also webcast an investor presentation on Sunday, June 27 at 7:30 PM ET. The annual meeting of the ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97f%FB%11z%7D%7F Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. This 26-week clinical study compared BYDUREON monotherapy to Januvia (sitagliptin), Actos (pioglitazone HCI) or metformin, three oral type 2 diabetes medications commonly prescribed early in the treatment of type 2 diabetes. Study participants were not achieving adequate A1C control using diet and exercise, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97f%FD%1C%7Fyr SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. DURATION-4 reinforced that a continued presence of exenatide helped these recently diagnosed patients to achieve glycemic control. The combination of efficacy, tolerability, and once weekly dosing in this monotherapy setting further supports the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97f%FD%11y%7C%7B SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97f%FD%11%7F%7F%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc. Our BioMAP human-based disease model is well-suited to assist Amylin in its search for new innovative treatments for inflammation. We look forward to assisting Amylin with this latest project, and other similar collaborations in the future. Under the agreement, BioSeek (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97f%FD%11%7Dx%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc. text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97f%FE%12yzy Highlighted Links Nat'l Employee Wellness Month Virgin HealthMiles BOSTON, MA and WASHINGTON, DC and SCOTTSDALE, AZ-(Marketwire - June 10, 2010) - In tandem with June's National Employee Wellness Month, Virgin HealthMiles, the Strategies to Overcome and Prevent (STOP) Obesity Alliance and the Institute for Health and Productivity Management have developed a collection of wellness resources and tools designed to help employers and employees create healthier workplaces. The collection of resources (featured at www.nationalemployeewellnessmonth.com) includes easy-to-implement workplace wellness program ideas, case studies of corporate and employee wellness innovators, whitepapers about (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v117/%3B%97f%FF%17%7C%7D%7E The objective of this Phase 4, open-label, multicentre, observational study was to fulfil food and drug administration (FDA) postapproval requirement to evaluate in healthcare practices the risk of insulin-induced severe hypoglycaemia following initiation of pramlintide therapy in N = 1297 patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) with inadequate glycaemic control. The duration of the study was approximately 6 months. During the adjustment period (0-3 months), the incidence and event rate of patient-ascertained severe hypoglycaemia (PASH) were 4.8% and 0.33 events/patient-year in patients with T1DM and 2.8% and 0.19 events/patient-year in patients (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v117/%3B%97g%F6%12zys 03.06.2010 - Amylin Pharmaceuticals, Inc. announced that Christian Weyer, MD has been appointed Senior Vice President, Research and Development. Orville Kolterman, MD, has been named Senior Vice President, Chief Medical Officer. These leadership changes will strengthen the Company's focus on preparations for a new product launch and the advancement of its late-stage development programs, both important value drivers for the Company. During his 10-year tenure at Amylin, Dr. Weyer has made valuable contributions to the business through leadership roles in the Research, Clinical, and Corporate Development organizations, most recently as Vice President, Medical Development. In his new role, (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97g%F6%10y%7Cr Hear what employers and employees are saying about workplace wellness. Highlighted Links National Employee Wellness Mo. 2010 Wellness Month Video BOSTON, MA and WASHINGTON, DC and SCOTTSDALE, AZ-(Marketwire - June 1, 2010) - Sixty-two percent of American businesses and nearly 85 percent of employees say the workplace must play a leadership role in creating a healthier workforce and helping to curb rising healthcare costs, according to a new survey released today by Virgin HealthMiles, a leading provider of employee wellness programs that pay people to get active. Even with the enactment of federal healthcare reform, 85 percent of U.S. companies surveyed believe the newly-enacted (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97g%F8%12txx The research team of The George Washington University School of Public Health and Health Services' Department of Health Policy's Strategies to Overcome and Prevent (STOP) Obesity Alliance received a $250,000 donation from Allergan, Inc. to support public health, policy analysis and research about the economic and health impact of obesity and related chronic diseases. The donation is part of Allergan, Inc.'s public awareness and advocacy campaign called C.H.O.I.C.E. - Choosing Health over Obesity Inspiring Change through Empowerment - which advocates for consumers, healthcare professionals and Congress to work together to successfully address the adult obesity epidemic through a dual focus (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97g%F8%17z%7C%7D Brisbane, Australia. 25 May 2010: Xenome Limited ( œXenome ) today announced the appointment of Michael Aldridge as Executive Director. Mr Aldridge brings to Xenome an extensive background in the global biotechnology and pharmaceutical industries having held leadership, strategic, consulting and financing roles in North American, European and Australian companies. As CEO, Board Director and Consultant with Peplin, Inc. from 2003 2009, Michael led the growth of a global, dermatology focused, product company developing a new approach to the treatment of skin cancer. Peplin was sold to LEO Pharma A/S, a European dermatology company, for US$287.5 million in cash in September 2009. ?Xenome (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97g%F9%17z%7C%7F MENLO PARK, Calif.-(BUSINESS WIRE)-Kleiner Perkins Caufield & Byers (KPCB), the Silicon Valley venture capital firm behind Genentech, today announced that Isaac Ciechanover (pronounced œsea-hanover ), M.D., has joined the firm as a Partner. He will provide counsel and guidance to the firm s network of life science entrepreneurs. KPCB has a history of supporting cutting-edge advancements in the life sciences and is known as a highly strategic resource for entrepreneurs, medical professionals and scientists. I look forward to working with a group of professionals I ve long respected For more than 15 years, Ciechanover has worked with entrepreneurs to advance medicine through innovation (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97g%FA%12x%7E%7D DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their diabetes research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the user The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. This dataset will also be relevant to those working in the area of drug delivery technologies, and to companies that supply labs involved in respiratory drug development. The database currently tags 202,240 individuals working in diabetes (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97g%FB%13%7Ez%7B BOTHELL, WA-(Marketwire - May 13, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the first quarter ended March 31, 2010, and recent corporate accomplishments. "As we close in on the end of the second quarter 2010, we see the last twelve months as a year of building," stated J. Michael French, President and Chief Executive Officer of MDRNA. "Whereas 2008-2009 was a year of transition, 2009-2010 was a year of building clinical pipelines, technology platforms, partnerships and a world-class research and management team. Besides significant advancements in our own efforts, we announced in April that we (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97g%FB%13%7Cx%7F WALTHAM, Mass.-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its fiscal year ended March 31, 2010, and provided financial expectations for fiscal 2011. Fiscal 2011 will be a transformational year for Alkermes as we continue to leverage our proprietary product platforms to advance and expand our pipeline. Financial highlights: Total revenues of $178.3 million for fiscal 2010. Record manufacturing and royalty revenues from RISPERDAL CONSTA of $146.0 million. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Cilag (Janssen) were approximately $1.5 billion in fiscal 2010, an 11.5 percent (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97g%FC%1Duzy Highlighted Links National Employee Wellness Month BOSTON, MA, and WASHINGTON, DC and PHOENIX, AZ-(Marketwire - May 11, 2010) - In June, Virgin HealthMiles, in partnership with the Strategies to Overcome and Prevent (STOP) Obesity Alliance and the Institute for Health and Productivity Management, will sponsor the second annual National Employee Wellness Month to raise public awareness about the critical role employers play in workplace wellness and how preventive, healthy employee behavior can help to improve health and combat our nation's rising healthcare costs. Even as healthcare reform is implemented, forward-looking businesses have recognized they must play a leadership role in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97g%FD%13xws SAN DIEGO, INDIANAPOLIS, & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON ¢ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010. We will continue to work closely with the agency through this final stage of the review process. œIf approved, BYDUREON will be the first once-weekly treatment for type 2 diabetes, and we are committed to making this important therapeutic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97g%FE%11%7B%7Dx ALISO VIEJO, Calif.-(BUSINESS WIRE)-AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the hiring of Michael McFadden as Vice President of U.S. Sales and Managed Markets. In this capacity, Mr. McFadden will be responsible for staffing, training and managing the planned Zenvia ¢ specialty sales force as well as overall leadership of all sales-related activities. In addition, in his capacity as managed markets leader, he will oversee the development of all strategies and activities related to national health plan account management, state Medicaid, trade relations, long term care, government affairs and contract administration. The hiring of Michael as Vice President of Sales (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97g%FF%15u%7Fx SAN DIEGO, April 27, 2010 /PRNewswire-FirstCall/ - Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN - News) will be presenting at the Deutsche Bank 35th Annual Healthcare Conference in Boston on Tuesday, May 4, 2010 at 10:40 a.m. ET / 7:40 a.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97g%FF%15%7E%7Cr SAN DIEGO, April 27, 2010 /PRNewswire-FirstCall/ - Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN - News) will webcast its Annual Meeting of Stockholders on Thursday, April 29, 2010 at 9:00 a.m. PT/ 12:00 p.m. ET from the Company's corporate headquarters in San Diego, CA. Following the Annual Meeting, Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v117/%3B%97%60%F7%1Cxwx Although the adipokine leptin is regarded as the prototypical long-term signal of energy balance, obese individuals are largely nonresponsive to exogenous leptin administration. Restoration of leptin responsiveness in obesity has been elusive despite a detailed understanding of the molecular mechanisms of leptin signaling. Recent translational research findings point to a potential therapeutic approach that incorporates amylin (a beta-cell hormone) and leptin agonism, with amylin restoring or enhancing leptin sensitivity. Here we hypothesize various physiological, neurobiological and molecular mechanisms that could mediate the interaction of these two neurohormonal signals and discuss (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%F7%12%7Bvs WALTHAM, Mass. & NEW YORK-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today will present an update on the progress of its late-stage and emerging clinical product candidates from the company s proprietary technology platforms at its Research and Development (R&D) Day for analysts and investors in New York. This is a particularly productive time in the company s history, as we expect significant inflection points on most of our key product candidates by the end of 2010. As part of the update on late-stage development programs, Alkermes will announce the royalty rate to be received on sales of BYDUREON ¢ (exenatide for extended-release injectable suspension). Alkermes will also (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%F7%12%7B%7E%7F PHILADELPHIA-(BUSINESS WIRE)-CIGNA Corporation (NYSE: CI) announced today that Joseph P. Sullivan, former chairman and chief executive officer of Protocare, Inc., a clinical trials and pharmaceutical industry consulting firm, will join CIGNA Corporation's board of directors effective April 27, 2010. He will be a member of the corporate governance committee and the people resources committee. We re really pleased to have Joe join our board. He brings a wealth of experience and knowledge in health care and health policy, an appreciation for our commitment to health improvement and wellness, and a terrific understanding of what it takes to be a growth company Sullivan has been a private (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%FA%1C%7F%7Dz SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON ¢ (exenatide for extended-release injectable suspension). In accordance with its guidelines, the FDA is expected to classify the complete response as a Class 1 or Class 2 resubmission, and also provide the companies with an updated Prescription Drug User Fee Act (PDUFA) target action date within (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%FA%1C%7F%7Cz NASHVILLE, Tenn.-(BUSINESS WIRE)-The Tennessee Biotech Association (TBA) today announced that life sciences entrepreneur and investor Joseph C. Cook, Jr., founder and chairman of the board of Ironwood Pharmaceuticals, Inc., has been elected to its Board of Directors. The Association also announced that public and government relations firm Hall Strategies has been selected to lead its daily operations beginning in July. Joe Rolwing has given his heart and soul to this organization over the past five years, and he ll continue to be an important part of our transition over the coming months œJoe Cook s experience in the life sciences sector adds a new dimension to our board at an important (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v117/%3B%97%60%FB%1C%7Exy OBJECTIVE: To review the possible association between glucagon-like peptide-1 (GLP-1) agonist use and pancreatitis in patients with type 2 diabetes mellitus. DATA SOURCES: A MEDLINE search (1950-January 2010) identified key clinical trials delineating adverse effects associated with GLP-1 agonist use. Key search terms included type 2 diabetes mellitus, pancreatitis, incretins, exenatide, liraglutide, albiglutide, and taspoglutide. Review of references listed in the articles identified was also performed. The Food and Drug Administration (FDA) Web site and Amylin Pharmaceuticals file data were utilized to extract case report information and unpublished clinical development data related to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97%60%FF%1D%7Bwy SAN DIEGO, April 19, 2010 /PRNewswire-FirstCall/ - Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009. GAAP net loss was $38.2 million, or $0.27 per share, for the quarter ended March 31, 2010, compared to $47.0 million, or $0.34 per share, for the same period in 2009. At March 31, 2010 the Company held cash, cash equivalents and short-term investments of $598.3 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97%60%FF%1D%7B%7Cy INDIANAPOLIS, April 19 /PRNewswire-FirstCall/ -Eli Lilly and Company today announced financial results for the first quarter of 2010.Due to significant strategic actions taken by the company, financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results exclude significant items described in the reconciliation tables. The non-GAAP results are presented in order to provide additional insights into the underlying trends in the company's business. The company's 2010 financial guidance (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%FF%12%7C%7C%7B DEERFIELD, Ill.-(BUSINESS WIRE)-Walgreen Co. (NYSE:WAG) (NASDAQ:WAG) today announced that Ginger L. Graham, President and CEO of Two Trees Consulting and a Harvard Business School faculty member, has been elected to its board of directors effective May 1. Graham, who joins the board as an independent director, becomes the board s 10th member. We look forward to the contributions she will make as the company plays an even larger role in meeting the nation s need for greater access to quality, affordable health care. œWe value the experience and insight from Ginger s career-long focus in developing strategies to bring innovative health care solutions to the market,  said Walgreens (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97%60%FF%13u%7Ez SAN DIEGO, April 12, 2010 /PRNewswire-FirstCall/ - Amylin Pharmaceuticals, Inc. will webcast its Quarterly Update Conference Call for the first quarter of 2010 on Monday, April 19, 2010 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2010. About Amylin PharmaceuticalsAmylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97%60%FF%13x%7D%7E April 9 (Bloomberg) - Amylin Pharmaceuticals Inc. and Eli Lilly & Co. s long-acting Byetta may be tied to increased cancer risk, a top U.S. regulator said, raising concerns that the experimental diabetes drug may need strict warnings. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97%60%FF%10t%7C%7C WASHINGTON-(BUSINESS WIRE)-The Biotechnology Industry Organization (BIO) announced the Business Forum company presentations to take place at the 2010 BIO International Convention. The global event for biotechnology will be held May 3-6 in Chicago, Ill. at McCormick Place. This year we expect to be booked solid again in our partnering presentations. We believe that this is a great venue to develop successful partnerships to develop vaccines for global health. Company presentations will provide valuable insight to the stories, pipelines, and partnering objectives of participating domestic and international companies in 35 different therapeutic and industry tracks, including leading (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97%60%FF%15%7B%7Ez BOTHELL, WA-(Marketwire - March 23, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fourth quarter and year ended December 31, 2009. Net loss for the fourth quarter of 2009 was approximately $0.8 million or $0.02 per share, compared to a net loss of approximately $12.3 million or $0.39 per share for the same period of 2008. The net loss for the year ended December 31, 2009 was approximately $8.0 million or $0.21 per share, compared to a net loss of approximately $59.2 million or $2.01 per share for the prior year period. "During 2009 we established ourselves as a leading RNAi therapeutics company by (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97%60%FF%15%7F%7Bs Brisbane, Australia. 23 March 2010: Xenome Limited ( œXenome ) today announced that MedImmune LLC ( ˜MedImmune ), the biologics unit of AstraZeneca, has exercised its option to obtain exclusive licenses to four peptides from Xenome s xdiscover ¢ venom peptide library against an undisclosed target involved in a key pain pathway. The decision to exercise this option follows an agreement announced in January 2009 between MedImmune and Xenome, under which MedImmune screened Xenome s xdiscover ¢ library of peptides. The financial terms of the licenses remain confidential, however Xenome will be eligible to receive undisclosed milestone and royalty payments associated with the ongoing (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97a%F6%16%7E%7Ex Primary care physicians agree they have a role in addressing obesity, but say they do not have the right weight management resources. Obese or heavier adults take responsibility for weight loss, but adults who need to lose weight may lack information about effective weight loss methods and strategies. These findings and others come from new research commissioned and released today by the Strategies to Overcome and Prevent (STOP) Obesity Alliance, a project operating out of the Department of Health Policy at The George Washington University School of Public Health and Health Services. In a national survey of 290 primary care physicians conducted by Harris Interactive by mail between (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97a%F6%16%7Dv%7E Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON (exenatide for extended-release injectable suspension). In the complete response letter there are no requests for new pre-clinical or clinical trials. Requests raised in the letter primarily relate to the finalization of the product labeling with accompanying Risk Evaluation and Mitigation Strategy (REMS) and clarification of existing manufacturing processes. The complete response letter does not contain requests related to the (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v117/%3B%97a%F7%10%7E%7D%7D Highlighted Links http:/www.nationalemployeewellnessmonth.com BOSTON, MA and WASHINGTON, DC and SCOTTSDALE, AZ-(Marketwire - March 15, 2010) - Today, Virgin HealthMiles, in partnership with the Strategies to Overcome and Prevent (STOP) Obesity Alliance and the Institute for Health and Productivity Management (IHPM), announced they will sponsor the second annual National Employee Wellness Month this June to raise awareness about the benefits of workplace wellness and educate business leaders and employees about how they can take steps to create healthier and more physically active workplace communities and lower overall healthcare costs. As part of June's National Employee Wellness Month, (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97a%F7%11uw%7D Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial. Similarly, treating multiple blood lipids with combination drug therapy of a fibrate and a statin did not reduce the combined risk of cardiovascular disease events more than treatment with statin alone. The study of more than 10,000 participants is sponsored by the National Institutes of Health. ACCORD (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97a%F7%11u%7Fy SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON (exenatide for extended-release injectable suspension). We have a clear path forward and are working diligently to submit our response to the FDA in the next few weeks. In the complete response letter there are no requests for new pre-clinical or clinical trials. Requests raised in the letter primarily relate to the finalization of the product labeling with (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v117/%3B%97a%F7%11zy%7F ScienceDaily (Mar. 14, 2010) Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial. See Also: Health & Medicine Hypertension Heart Disease Cholesterol Diabetes Blood Clots Personalized Medicine Reference Low density lipoprotein Hypercholesterolemia High density lipoprotein Cholesterol Similarly, treating multiple blood lipids with combination drug (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v117/%3B%97a%F9%13%7Cxr Cholecystokinin (CCK) acutely synergizes with amylin to suppress food intake in lean mice. To extend on these findings, the present studies sought to identify neural correlates for the interaction of amylin and CCK, as well as further understand the therapeutic potential of CCK-based combinations in obesity. First, c-Fos activation was assessed in various brain nuclei after a single intraperitoneal injection of amylin (5microg/kg) and/or CCK (5microg/kg). Amylin and CCK additively increased c-Fos within the area postrema (AP), predominantly in noradrenergic (e.g., dopamine-beta-hydroxylase-containing) cells. Next, amylin (100 or 300mug/kg/d) and/or CCK (100 or 300mug/kg/d) were (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97a%F9%11%7Cw%7D ATLANTA-(BUSINESS WIRE)-Implantable Provider Group (IPG), a leading provider of implantable device management, announced today that it has secured an investment from Sequoia Capital. The funding will enable IPG to invest in future growth initiatives. The company is addressing a significant need in the health care industry. Our services are directly in line with the needs of the health care industry right now, said Jay Ethridge, CEO of IPG. Given the current environment, it is critical that commercial insurance companies find ways to reduce costs without compromising patient care. IPG enables payers to do exactly that by reducing the cost of implantable devices without any change in the (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v117/%3B%97a%FA%12%7D%7Dx Cymetrix Board Member, Joseph Sullivan, receives award for Corporate Growth and Development from the Forum for Corporate Directors IRVINE, Calif., March 4 /PRNewswire/ - Cymetrix Board Member Joe Sullivan was recognized by the Forum for Corporate Directors as a 2010 Director of the Year Honoree. He was recognized in the category of Corporate Growth and Development for playing a significant role in enhancing the growth and operations of the companies he serves. Sullivan has served on the board of Cymetrix, Inc., an industry leader providing hospitals and health care networks with adaptive revenue cycle management solutions, since 2006. In addition to Cymetrix, Sullivan is also a board (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v117/%3B%97a%FC%1Cuy%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a9dd3e/eli_lilly_pipelin) has announced the addition of the "Eli Lilly: Pipeline, Products, Performance and Potential" company profile to their offering. Eli Lilly: Pipeline, Products, Performance and Potential Eli Lilly is a global manufacturer and distributor of pharmaceutical therapies for cancer, cardiovascular diseases, central nervous system ailments, diabetic and endocrine system disorders, and infectious diseases. Lilly's top selling product is Zyprexa, an antipsychotic for the treatment of schizophrenia, with sales in 2008 of over US$4.6 billion. Lilly has been in operation for 120 years, in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97a%FC%16%7B%7Fz SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA). The revised action date is the result of the FDA s decision to allow five additional days for its review of pending regulatory applications following the agency's recent five-day weather-related closure. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v117/%3B%97a%FC%16zyr SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., Feb. 25, 2010 /PRNewswire-FirstCall/ - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA). The revised action date is the result of the FDA's decision to allow five additional days for its review of pending regulatory applications following the agency's recent five-day weather-related closure. Exenatide once weekly is an investigational, extended-release medication for type 2 (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v117/%3B%97a%FC%16%7Fyz Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss. "There is an enormous unmet need to help reduce the individual and economic burden of obesity," said Christian Weyer, M.D., vice (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v117/%3B%97a%FC%15%7F%7Ex NEW YORK, Feb. 23 /PRNewswire/ - Carl Icahn announced today that he and his affiliated entities notified Genzyme Corporation (Nasdaq: GENZ) on Friday, February 19, 2010, of their intention to nominate 4 director candidates at the 2010 annual meeting of Genzyme shareholders. Mr. Icahn stated that "Our slate consists of Dr. Alex Denner, who is a managing director of entities that advise Icahn managed hedge funds, Dr. Richard Mulligan of the Harvard Medical School, Dr. Steven J. Burakoff, of the Mount Sinai School of Medicine and myself." Mr. Icahn further stated that, "both Dr. Mulligan and Dr. Burakoff are brilliant members of the medical community and will add much practical and (…)